On this page · 9 sections
PI3K inhibitors oral tablet (3 mg; 9 mg)

Inavolisib

Generic name: inavolisib

Brand names: Itovebi

Last updated November 2, 2026 0 views
Share

What is inavolisib?

Inavolisib is used along with other cancer treatments to treat adults with breast cancer that has spread to other parts of the body (metastatic) and has returned after treatment with medicines.

Your doctor will conduct tests to ensure that inavolisib is the right treatment for you.

Inavolisib may also be used for reasons not mentioned in this medication guide.

This section was rewritten for readability and reviewed for meaning.

How should I take inavolisib?

Follow all directions on your prescription label and read all medication guides or instruction sheets. Use the medicine exactly as directed.

Inavolisib is usually taken once per day with or without food at the same time each day.

If you vomit shortly after taking inavolisib, do not take another dose. Take your next dose as scheduled.

You may be given other medications. Keep taking these medicines for as long as your doctor has prescribed.

Do not change your dose or stop using this medicine without your doctor's advice.

Your blood may need to be tested often.

Your blood sugar will also need to be checked before and during treatment.

Swallow the tablet whole and do not crush, chew, or break it.

Store at room temperature away from moisture and heat.

This section was rewritten for readability and reviewed for meaning.

Warnings

Use only as directed. Inform your doctor if you are taking other medicines or have other medical conditions or allergies.

This section was rewritten for readability and reviewed for meaning.

Before taking this medicine

You should not take inavolisib if you are allergic to it.

Tell your doctor if you have or have ever had:

  • diabetes or high blood sugar; or
  • kidney disease.

You may need to have a negative pregnancy test before starting this treatment.

Both men and women using inavolisib should use effective birth control to prevent pregnancy. Inavolisib can harm an unborn baby if the mother or father is using this medicine.

Keep using birth control for at least 1 week after your last dose. Tell your doctor right away if a pregnancy occurs.

Inavolisib may affect fertility in men or women. Pregnancy may be less likely to occur while the mother or the father is using this medicine. Both men and women should still use birth control to prevent pregnancy because the medicine can harm an unborn baby.

Do not breastfeed while using this medicine, and for at least 1 week after your last dose.

This section was rewritten for readability and reviewed for meaning.

Inavolisib side effects

Get emergency medical help if you have signs of an allergic reaction: hives, difficulty breathing, swelling of your face, lips, tongue, or throat.

Inavolisib may cause serious side effects. Call your doctor right away if you experience:

  • high blood sugar--increased thirst, increased urination, dry mouth, fruity breath odor;
  • nausea, vomiting;
  • blurred vision;
  • confusion;
  • weight loss, increased appetite;
  • severe diarrhea, blood in your stools, stomach pain; or
  • blisters or ulcers in your mouth, red or swollen gums, trouble swallowing.

Your cancer treatments may be delayed or stopped for good if you have certain side effects.

Common side effects of inavolisib may include:

  • abnormal lab results;
  • loss of appetite;
  • rash;
  • headache;
  • feeling weak or tired;
  • nausea; or
  • new or worsening cough, fever, trouble breathing.

This is not a complete list of side effects, and others may happen. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

This section was rewritten for readability and reviewed for meaning.

Inavolisib dosing information

Usual Adult Dose for Breast Cancer:

9 mg orally once a day, in combination with palbociclib and fulvestrantDuration of therapy: Until disease progression or unacceptable toxicity Comments:-Ensure patients meet criteria for treatment based on PIK3CA cancer mutations. -For pre- or perimenopausal women, administer a luteinizing hormone-releasing hormone (LHRH) agonist. -Consider administering a LHRH agonist in men. -Refer to the manufacturer product information for palbociclib and fulvestrant for complete dosing and administration recommendations. Use: In combination with palbociclib and fulvestrant, for the treatment of endocrine-resistant, PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer following recurrence on or after completing adjuvant endocrine therapy

What happens if I miss a dose?

Use the medicine as soon as you can, but skip the missed dose if you are more than 9 hours late for the dose. Do not use two doses at one time.

This section was rewritten for readability and reviewed for meaning.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

  • Follow your doctor's instructions about any restrictions on food, beverages, or activity.

This section was rewritten for readability and reviewed for meaning.

What other drugs will affect inavolisib?

Other drugs may affect inavolisib, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.

This section was rewritten for readability and reviewed for meaning.

Related medicines

Before you take this medicine: the information on this page is general and may not cover your personal circumstances. Read the label supplied with your medicine and ask a pharmacist or doctor if you are unsure, especially if you are pregnant, breastfeeding, taking other medicines or managing a long-term condition.
General medicine information Consumer-friendly language

Content is provided for education and is not medical advice. See our medical disclaimer.